Intercure opened higher at $3.94, compared with its previous close of $3.91. In the last trading session, the stock traded between $3.73 and $3.98. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Intercure is now worth
$ 48.35
Resulting in a loss of
$ 51.65 (51.65%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
$-0.11 (-2.69%)
Day High
$3.98
Day Low
$3.73
Day Open
$3.94
Prev Close
$3.91
Volume
6,851
1W Return
6.14%
1M Return
-22.66%
3M Return
289.06%
6M Return
363.97%
1Y Return
169.86%
Market Cap ($ Mn)
45
PE Ratio
-
PB Ratio
0.51
PEG Ratio
-
ROE
-9.01%
ROCE
-4.99%
EPS (TTM)
$0.54
1 Week
6.14%
1 Month
-22.66%
3 Months
289.06%
6 Months
363.97%
9 Months
318.13%
InterCure regains Nasdaq compliance after bid price notice
InterCure received written confirmation of regained compliance with Nasdaq Listing Rule 5450(a)(1). The update reverses a September 1, 2026 notice indicating potential delisting from the Nasdaq Global Market. The company satisfied the minimum bid price requirement set by the exchange. No financial metrics or operational updates were provided in the announcement.
2mo agoInterCure settles war damage claim for NIS 230 million to rebuild Nir Oz
InterCure settled war damage claim for NIS 230 million with Israeli tax authorities. Total compensation including advances reaches NIS 331 million, exceeding initial claim. Funds will accelerate rehabilitation of damaged Nir Oz cultivation facility. CEO cites U.S. regulatory reassessments as validation for pharma-grade vision.
2mo agoInterCure effects 1-for-5 reverse split to meet Nasdaq bid price
InterCure Ltd. announced a one-for-five reverse share split effective August 24, 2026, aimed at regaining compliance with Nasdaq's $1.00 minimum bid price requirement. The move reduces authorized shares from 100 million to 20 million and outstanding shares from approximately 59.2 million to 11.8 million. Shareholders approved the split on August 11, 2026, and the company expects to appeal any delisting determination during the compliance period.
2mo agoInterCure secures NIS 22M in private placement led by pharma funds
InterCure Ltd. has secured NIS 22 million in funding through a private placement led by its CEO and pharma-focused hedge funds, with proceeds potentially rising to NIS 54 million. The issuance includes 7,895,143 ordinary shares at NIS 2.75 per share and warrants exercisable in five years. The capital supports global expansion, particularly in Germany and regulated U.S. markets.
4mo agoInterCure closes Botanico tranche, eyes U.S. medical market
InterCure Ltd. completed the initial closing of its acquisition of Botanico Ltd., issuing 2,471,061 ordinary shares to secure exclusive rights to U.S. cannabis genetics and AI-driven technologies. Following the U.S. federal rescheduling of medical cannabis, InterCure is reviewing opportunities in regulated markets. The company also reported growing demand in Germany, with new product launches expected later this year.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in Intercure is now worth
$ 48.35
Resulting in a loss of
$ 51.65 (51.65%)
Note: Past profits do not guarantee future returns.
